One Small Stock to Own for eSports Growth

Oct 15, 2020

/

01:38 AM PST

Rating

No ratings


The idea of a "megatrend" is one we've discussed before. Although economic cycles repeat themselves over and over again, favoring different sectors at different times, a "megatrend" is a once-in-a-lifetime change... an opportunity that's bigger than any economic cycle. Sometimes they're so big they're difficult to recognize. For investors savvy enough to see the writing on the wall though, the reward can be massive.


Well, we think we've identified such an opportunity in its infancy right now, and we've uncovered a company that looks like an ideal way to plug into this budding trend. That company? SPYR Inc. (OTCMKTS:SPYR).

Phase 1 Hair-Replacement Trial Goals Met: RepliCel Life Sciences (REPCF, CVE:RP)

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Did everyone who wanted into RepliCel Life Sciences (REPCF, CVE:RP) back on February 15th -- when we first told you about it -- get into their position? We hope so. This morning the company announced something we weren't entirely surprised to hear, but were still very pleased to learn. That is, RepliCel has completed Phase 1 of a key trial of one its products, and things look great.


We'll look at it below (the whole press release appears at the bottom of today's newsletter), but first we want to play a little catch-up for anyone who may have missed the first look.


RepliCel Life Sciences is working on a trio of treatments, all of which are ultimately rooted in the same cell therapy science. Those projects are therapies for degenerating tendons, aging or UV-damaged skin, and pattern baldness. And, in what's officially a separate trial, the company is developing a dermal-injector device that administers two of the three therapies in the pipeline.

Algae Dynamics (ADYNF) and Patriot One (PTOTF) - A Double Dose of Good News

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

As the saying goes, when it rains, it pours.... not that we mind, when what's pouring is a double-dose of good news about not one but two of our Featured Stocks.


That's exactly what we've got today, by the way. Just when we were putting the finishing touches on our thoughts regarding this morning's news from Algae Dynamics (ADYNF), we saw Patriot One Technologies (CVE:PAT, PTOTF) served up some news as well. They were both so exciting, we had to make sure all of you heard about each announcement. In no particular order...


This morning, Algae Dynamics announced it had signed a deal with the University of Western Ontario to research and develop new cannabis-based drugs. ADYNF will provide funding, and the university will provide the work and know-how.

Did You See the Oil Selloff Coming? This Guy Did.

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

Amazing. Just amazing. Right when you think you can't be any more impressed, you become a little more impressed.


I'm talking about John Monroe over at the Elite Opportunity Pro service. In Wednesday afternoon's edition of the EO Pro newsletter he made a bearish call on oil I wasn't quite so sure about. I became much more convinced in the meantime, with oil prices falling in a big way shortly after he predicted it. Crude was at $52.48 per barrel then, and now it's at $48.98. That's a very trade-worthy 6% move. If you played that with a put option or crude oil futures, you could have magnified the move even more. Not bad for one day's work.


How does he do it?

The Cell MedX (CMXC) Ball is Officially Rolling

Jul 9, 2020

/

01:13 PM PST

Rating

No ratings

And so it begins. Cell MedX (OTCQB:CMXC) -- the company developing a bioelectric device to treat diabetes and some of its effects -- announced on Thursday morning that the first participants in a pivotal trial have been identified and approved. The testing, which should be completed within four to six months, will seek to verify that use of the company's eBalance technology lowers blood sugar for Type 1 and Type 2 diabetics. In previous observational testing, that result was seen... along with other demonstrable health benefits. The company and its shareholders are understandably excited to begin these clinical trials.


The underlying science of electromedicine isn't exactly brand new, but it is understudied... especially given its potential.


The premise is simple enough. That is, each cell in the human body isn't just a collection of biological structures and organic chemical reactions. By design, they also emit and respond to electrical currents. By tweaking the amount of current delivered to a damaged cell or group of cells, they can often be restored to their full functionality. Conversely, cells that are damaged beyond repair (like cancerous cells) can have their self-destruct programming bolstered by waves of electricity.

<<37  38  39  40  41  42  43  44  45  46  >>